Acutis Biotherapeutics to Announce Third Quarter Results After Market Close on November 4
ARQT Arcutis Biotherapeutics Inc
$25.55 -5.37%
View chart & analysis → - 1Wall Street revenue estimates stand at $141.6 million with an expected earnings per share of $0.17.
- 2Acutis Biotherapeutics raised its 2026 net product sales guidance to a range of $525 million to $540 million.
- 3Chief Commercial Officer Todd Edwards has left the company.
So what's the key point?
Acutis Biotherapeutics has raised its future sales outlook ahead of its earnings announcement. Market expectations and changes in management are also drawing attention.
Source Earnings Whispers · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.